Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740

Inclusion criteria

• Males or females, of any race, between 18 and 55 years of age, inclusive.
• Body mass index between 18.0 and 32.0 kg/m2, inclusive.
• In good health, determined by no clinically significant findings as assessed by the investigator.
• Adhere to all contraception criteria.

Exclusion criteria

• Significant medical history as determined by the investigator.
• History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, including itraconazole, unless approved by the investigator (or designee).
• History of stomach or intestinal surgery or resection that would potentially alter absorption or excretion of orally administered drugs (uncomplicated appendectomy and hernia repair will be allowed).
• Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, as judged by the investigator.
• History or presence of an abnormal ECG.
• Use or intend to use any medications/products/herbal remedies known to alter drug absorption, metabolism, or elimination processes, including St. John's wort, within 30 days prior to check-in, unless deemed acceptable by the investigator (or designee).
• Drugs affecting CYP3A4 should be refrained from use for 3 weeks, or 5 half-lives (whichever is longer), prior to check-in through to follow-up.
• Positive urine drug screen at screening or positive alcohol breath test result or positive urine drug screen at check-in.21. History of alcoholism or drug/chemical abuse within 12 months prior to check-in.
• Ingestion of poppy seed, Seville orange, or grapefruit containing foods or beverages within 7 days prior to check-in.